Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026

Arcutis Biotherapeutics announced it will report third quarter 2026 financial results and provide a business update on November 4, 2026, followed by a conference call at 4:30 p.m. ET. The commercial-stage biopharmaceutical company focuses on developing treatments for chronic inflammatory skin diseases.

10/21/2026, 4:00 PM • GlobeNewswire

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Arcutis Biotherapeutics presented clinical data for ZORYVE (roflumilast) across multiple inflammatory skin conditions at major dermatology conferences. The INTEGUMENT-INFANT trial showed the drug was well-tolerated in infants aged 3-24 months with atopic dermatitis, with 34.4% achieving disease clearance at 4 weeks. Additional analyses demonstrated ZORYVE's efficacy in treating psoriasis on special sites including the scalp and genitals, with improvements in sexual function and quality of life. Real-world research highlighted concerns about long-term topical corticosteroid use, including skin thinning and systemic side effects, positioning ZORYVE as a potential alternative therapy.

10/09/2026, 8:00 AM • GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics announced the grant of 62,500 restricted stock units (RSUs) to six newly hired employees as a material inducement for employment. The RSUs will vest over four years with 25% vesting annually, subject to continued employment. The grants were approved by the Compensation Committee under the company's 2022 Inducement Plan.

10/02/2026, 4:00 PM • GlobeNewswire

Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - SNS Insider

The global atopic dermatitis drugs market is projected to grow from USD 15.92 billion in 2025 to USD 33.42 billion by 2035, driven by increased adoption of biologic therapies, JAK inhibitors, and novel treatments. North America leads with 36% market share, while Asia-Pacific shows the fastest growth. Biologics dominate with 42% market share, though high costs and JAK inhibitor safety warnings present challenges.

09/04/2026, 8:30 PM • GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics announced the grant of 57,000 restricted stock units (RSUs) to 11 newly hired employees as a material inducement for employment. The RSUs will vest over four years with 25% vesting annually, subject to continued employment. The company also announced that management will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026.

09/04/2026, 4:00 PM • GlobeNewswire

Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced it will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026, in New York. Management will participate in a fireside chat on Wednesday, September 16 at 1:50 p.m. ET. The company focuses on developing targeted topicals for chronic inflammatory skin diseases.

09/02/2026, 4:00 PM • GlobeNewswire

Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability

Arcutis Biotherapeutics CEO Todd Watanabe sold 4,375 shares for $114,275 on August 3, 2026, to cover tax withholding obligations on vesting restricted stock units. The sale is non-discretionary and does not signal a change in management sentiment. Meanwhile, Arcutis reported strong Q2 2026 results with its flagship product Zoryve generating $129.9 million in revenue (59% growth) and the company achieving profitability with $15 million net income. The company raised full-year guidance to $525-540 million and received FDA approval to expand Zoryve's indication to treat plaque psoriasis in children as young as age 2.

08/06/2026, 8:30 AM • The Motley Fool

Arcutis Expands Board of Directors with Appointment of Chris Peetz

Arcutis Biotherapeutics announced the appointment of Christopher Peetz, CEO of Mirum Pharmaceuticals, to its Board of Directors effective July 15, 2026. Peetz brings extensive biopharmaceutical leadership experience from roles at multiple companies including Onyx Pharmaceuticals and Tobira. The appointment comes as Arcutis continues to expand its ZORYVE (roflumilast) franchise for treating inflammatory skin diseases and evaluates pipeline expansion through strategic acquisitions.

07/16/2026, 9:00 AM • GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

The FDA has approved ZORYVE cream 0.3% for treating plaque psoriasis in children as young as age 2, marking the first once-daily, non-steroidal therapy for this indication. This is Arcutis' seventh FDA approval for ZORYVE in four years. The approval addresses a significant treatment gap for young children with plaque psoriasis, offering a steroid-free option suitable for use anywhere on the body with no duration restrictions.

06/29/2026, 7:06 PM • GlobeNewswire

Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%

Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares worth $121,000 on June 15, 2026, under a pre-arranged trading plan. The sale reduced her stake by 15% but she retains over 27,500 shares. The insider transaction appears routine amid strong company performance, with ZORYVE revenue climbing 65% year-over-year to $105.4 million in Q1, and the company narrowing quarterly losses while maintaining positive cash flow.

06/23/2026, 7:15 PM • The Motley Fool

Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors

Antag Therapeutics announced the election of Keith Leonard as Chairman of its Board of Directors. Leonard brings 30 years of biopharmaceutical industry experience, including previous roles as Chairman and CEO of Unity Biotechnology and co-founder/CEO of Kythera Biopharmaceuticals. The appointment comes as Antag prepares to initiate Phase 2a trials of AT7687, its lead GIPR antagonist candidate for obesity treatment.

06/09/2026, 7:00 AM • GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics granted an aggregate of 44,000 restricted stock units to six newly hired employees as a material inducement for employment. The RSUs vest over four years with 25% vesting annually, subject to continuous employment. The grants were approved by the Compensation Committee under the company's 2022 Inducement Plan.

06/05/2026, 4:00 PM • GlobeNewswire

Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

Arcutis Biotherapeutics announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, in Miami. The commercial-stage biopharmaceutical company, focused on immuno-dermatology innovations, will participate in a fireside chat. The company also reported first quarter 2026 financial results and provided a business update.

05/26/2026, 4:00 PM • GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics granted 269,000 restricted stock units and options for 70,000 shares to 40 newly hired employees as inducement awards. The company also submitted a supplemental New Drug Application to the FDA to expand ZORYVE cream's indication to treat atopic dermatitis in infants as young as 3 months, supported by Phase 2 study data.

05/08/2026, 4:00 PM • GlobeNewswire

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics reported Q1 2026 net product revenue of $105.4 million for ZORYVE (roflumilast), representing 65% year-over-year growth despite 17% sequential decline due to typical Q1 seasonality. The company submitted a supplemental New Drug Application to expand ZORYVE cream 0.05% for treating atopic dermatitis in infants ages 3-24 months, completed enrollment in a foam formulation trial for pediatric psoriasis, and initiated a Phase 1 study for investigational ARQ-234. The company maintained positive operating cash flow of $2.2 million and reaffirmed full-year 2026 revenue guidance of $480-495 million.

05/06/2026, 4:00 PM • GlobeNewswire